Characterization of uptake of the new PET imaging compound 18F-fluorobenzyl triphenyl phosphonium in dog myocardium.

UNLABELLED 18F-Labeled p-fluorobenzyl triphenyl phosphonium cation (18F-FBnTP) is a member of a new class of positron-emitting lipophilic cations that may act as myocardial perfusion PET tracers. Here, we characterize the 18F-FBnTP uptake and retention kinetics, in vitro and in vivo, as well as the myocardial and whole-body biodistribution in healthy dogs, using PET. METHODS Time-dependent accumulation and retention of 18F-FBnTP in myocytes in vitro was studied. Seven anesthetized, mongrel dogs underwent dynamic PET scans of the heart after intravenous administration of 126-240 MBq 18F-FBnTP. In 4 of the 7 dogs, at the completion of a 60-min dynamic scan, whole-body scans (4 bed positions, 5-min emission and 3-min transmission per bed) were acquired. Arterial blood samples were collected at 0, 5, 10, 20, 30, and 60 min after administration, plasma activity was counted, and high-performance liquid chromatographic analyses for metabolites were performed. The extent of defluorination was assessed by measuring 18F-FBnTP bone uptake in mice, compared with 18F-fluoride. RESULTS The metabolite fraction comprised <5% of total activity in blood at 5 min and gradually increased to 25% at 30 min after injection. In vivo, 18F-FBnTP myocardial concentration reached a plateau level within a few minutes, which was retained throughout the scanning time. In contrast, activity in the blood pool and lungs cleared rapidly (half-life = 19.5 +/- 4.4 and 30.7 +/- 11.6 s, respectively). Liver uptake did not exceed the activity measured in the myocardium. At 60 min, the uptake ratios of left ventricular wall to blood, lung, and liver (mean of 7 dogs) were 16.6, 12.2, and 1.2, respectively. Summation of activity from 5 to 15 min and from 30 to 60 min after injection produced high-quality cardiac images of similar contrast. Circumferential sampling and a polar plot revealed a uniform distribution, near unitary value, throughout the entire myocardium. The mean coefficient of variance, on 30- to 60-min images along the septum-to-anterior wall and the apex-to-base axes was 7.58% +/- 1.04% and 6.11% +/- 0.89% (mean +/- SD; n = 7), respectively, and on 5- to 15-min images was 7.25% +/- 1.43% and 6.12% +/- 1.88%, respectively. 18F-FBnTP whole-body distribution was highly organ specific with the kidney cortex being the major target organ, followed by the heart and the liver. CONCLUSION 18F-FBnTP is a promising new radionuclide for cardiac imaging using PET with rapid kinetics, uniform myocardial distribution, and favorable organ biodistribution.

[1]  C. Nanni,et al.  Myocardial SPECT: what do we gain from attenuation correction (and when)? , 2004, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[2]  R. Dannals,et al.  Radiosynthesis of 3-[18F]fluoropropyl and 4-[ 18F]fluorobenzyl triarylphosphonium ions , 2004 .

[3]  M. D. Di Carli,et al.  Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. , 2003, Journal of the American College of Cardiology.

[4]  A. Yıldız,et al.  The effects of solid food in prevention of intestinal activity in Tc-99m tetrofosmin myocardial perfusion scintigraphy , 2003, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[5]  A. Sinusas,et al.  Comparison of Tl-201 with Tc-99m-labeled myocardial perfusion agents: Technical, physiologic, and clinical issues , 2001, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[6]  R. Winslow,et al.  Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure, II: model studies. , 1999, Circulation research.

[7]  M. Murphy,et al.  Selective targeting of bioactive compounds to mitochondria. , 1997, Trends in biotechnology.

[8]  J. Taki,et al.  Impaired fatty acid uptake in ischemic but viable myocardium identified by thallium-201 reinjection. , 1996, American heart journal.

[9]  R. Hendel,et al.  Myocardial Perfusion Imaging With 99mTc Tetrofosmin : Comparison to 201Tl Imaging and Coronary Angiography in a Phase III Multicenter Trial , 1995 .

[10]  L. Becker,et al.  Myocardial perfusion with [11C]methyl triphenyl phosphonium: measurements of the extraction fraction and myocardial uptake. , 1994, Journal of nuclear biology and medicine.

[11]  O Muzik,et al.  Early Detection of Abnormal Coronary Flow Reserve in Asymptomatic Men at High Risk for Coronary Artery Disease Using Positron Emission Tomography , 1994, Circulation.

[12]  A. Sinusas,et al.  Technetium-99m-tetrofosmin to assess myocardial blood flow: experimental validation in an intact canine model of ischemia. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  P. Slomka,et al.  Investigation of Measures to Reduce Interfering Abdominal Activity on Rest Myocardial Images With Tc-99m Sestamibi , 1993, Clinical nuclear medicine.

[14]  N. Shuke,et al.  Myocardial perfusion imaging and dynamic analysis with technetium-99m tetrofosmin. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  L. Shaw,et al.  Comparison of accuracy for detecting coronary artery disease and side-effect profile of dipyridamole thallium-201 myocardial perfusion imaging in women versus men. , 1992, The American journal of cardiology.

[16]  M. Verani,et al.  Quantitative thallium-201 single-photon emission computed tomography during maximal pharmacologic coronary vasodilation with adenosine for assessing coronary artery disease. , 1991, Journal of the American College of Cardiology.

[17]  M E Phelps,et al.  13N ammonia myocardial imaging at rest and with exercise in normal volunteers. Quantification of absolute myocardial perfusion with dynamic positron emission tomography. , 1989, Circulation.

[18]  R. Okada,et al.  Myocardial kinetics of technetium-99m-hexakis-2-methoxy-2-methylpropyl-isonitrile. , 1988, Circulation.

[19]  D. Kuhl,et al.  N‐13 Ammonia as an Indicator of Myocardial Blood Flow , 1981, Circulation.

[20]  E A Liberman,et al.  Conversion of biomembrane-produced energy into electric form. I. Submitochondrial particles. , 1970, Biochimica et biophysica acta.

[21]  Josef Machac,et al.  Cardiac positron emission tomography imaging. , 2005, Seminars in nuclear medicine.

[22]  S. Bergmann,et al.  Myocardial perfusion imaging agents: SPECT and PET , 2004, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[23]  D. Kass,et al.  Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure, I: experimental studies. , 1999, Circulation research.

[24]  P Suetens,et al.  A study of the liver-heart artifact in emission tomography. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  R. Hendel,et al.  Myocardial perfusion imaging with 99mTc tetrofosmin. Comparison to 201Tl imaging and coronary angiography in a phase III multicenter trial. Tetrofosmin International Trial Study Group. , 1995, Circulation.

[26]  F. Smith,et al.  Technetium-99m-1,2-bis[bis(2-ethoxyethyl) phosphino]ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.